Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CD96 Protein (CD96) (AA 22-503) (Fc Tag)

CD96 Origine: Humain Hôte: HEK-293 Cells Recombinant >90 % as determined by reduced SDS-PAGE. Active
N° du produit ABIN6253540
  • Antigène Voir toutes CD96 Protéines
    CD96
    Type de proteíne
    Recombinant
    Activité biologique
    Active
    Attributs du protein
    AA 22-503
    Origine
    • 14
    • 3
    • 1
    • 1
    • 1
    Humain
    Source
    • 12
    • 2
    • 2
    • 2
    • 1
    • 1
    HEK-293 Cells
    Purification/Conjugué
    Cette CD96 protéine est marqué à la Fc Tag.
    Séquence
    AA 22-503
    Attributs du produit
    This protein carries a mouse IgG2a Fc tag at the C-terminus. The protein has a calculated MW of 80.6 kDa. The protein migrates as 32 KDa, 34 KDa and 120 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
    Pureté
    >90 % as determined by reduced SDS-PAGE.
    niveau d'endotoxine
    Less than 0.1 EU per μg by the LAL method.
    Top Product
    Discover our top product CD96 Protéine
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Buffer
    Tris with Glycine, Arginine and NaCl,  pH 7.5
    Conseil sur la manipulation
    Please avoid repeated freeze-thaw cycles.
    Stock
    -20 °C
  • Antigène
    CD96
    Autre désignation
    CD96 (CD96 Produits)
    Synonymes
    1700109I12Rik Protein, Tactile Protein, TACTILE Protein, CD96 antigen Protein, CD96 molecule Protein, Cd96 Protein, CD96 Protein
    Sujet
    The progression of pancreatic cancer (PC) is significantly associated with tumor immune escape, which may be associated with nature killer (NK) cell dysfunction. CD226, CD96, and TIGIT, which share the ligand CD155, play important roles in the regulation of NK cell function. The present study was conducted to investigate the roles of these molecules in NK cells from PC patients. TIGIT and CD96 together with the co-stimulatory receptor CD226 form a pathway that is analogous to the CD28/CTLA-4 pathway, in which shared ligands and differential receptor:ligand affinities fine-tune the immune response. Although the roles of TIGIT and CD96 as immune checkpoint receptors in T cell and natural killer cell biology are just beginning to be uncovered, accumulating data support the targeting of these receptors for improving anti-tumor immune responses. A clear understanding of the immune cell populations regulated by TIGIT and CD96 is key to the design of immunotherapies that target these receptors in combination with other existing immune checkpoint blockade therapies. The dysfunction of CD96 may trigger C syndrome: A syndrome characterized by trigonocephaly, severe mental retardation, hypotonia, variable cardiac defects, redundant skin, and dysmorphic facial features, including upslanted palpebral fissures, epicanthal folds, depressed nasal bridge, and low-set, posteriorly rotated ears.
    Poids moléculaire
    80.4 kDa
    NCBI Accession
    NP_005807
Vous êtes ici:
Support technique